SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Science gains as its arm gets EIR from USFDA for Florida facility

20 Jan 2020 Evaluate

Strides Pharma Science is currently trading at Rs. 388.80, up by 2.00 points or 0.52% from its previous closing of Rs. 386.80 on the BSE.

The scrip opened at Rs. 389.40 and has touched a high and low of Rs. 393.00 and Rs. 388.40 respectively. So far 7724 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 550.40 on 22-Jan-2019 and a 52 week low of Rs. 288.00 on 09-Oct-2019.

Last one week high and low of the scrip stood at Rs. 395.80 and Rs. 384.85 respectively. The current market cap of the company is Rs. 3463.90 crore.

The promoters holding in the company stood at 31.28%, while Institutions and Non-Institutions held 46.45% and 22.27% respectively.

Strides Pharma Science’s step down subsidiary -- Strides Pharma Inc. (SPI), has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its facility in Riviera Beach, Florida, US.

The EIR was issued as an outcome of the USFDA’s inspection of the facility in December 2019. This facility is one of the very few manufacturing facilities in the US with a soft gel capsule (SGC) manufacturing suite for formulations with containment needs.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

1036.35 -16.90 (-1.60%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×